论文部分内容阅读
目的：观察大鼠ＢＥＲＨ－２肝癌细胞与自体激活Ｂ细胞的融合细胞作为疫苗抗肿瘤作用的特异性，并观察该肝癌疫苗体内抗肿瘤作用与Ｔ细胞亚群的关系。方法：（１）应用聚乙二醇（ＰＥＧ）融合大鼠ＢＥＲＨ－２肝癌细胞与激活Ｂ细胞制备细胞融合大鼠肝癌疫苗；（２）事先经该肝癌疫苗免疫的大鼠分别接种肝癌ＢＥＲＨ－２细胞和大鼠膀胱癌ＮＢＴ－Ⅱ细胞，观察该肝癌疫苗抗肿瘤作用的特异性；（３）该肝癌疫苗免疫大鼠之前或之后，以小鼠抗大鼠ＣＤ４单抗或抗ＣＤ８单抗多次注射，以清除大鼠ＣＤ４＋或ＣＤ８＋Ｔ细胞，随后观察大鼠的成瘤性。结果：ＢＥＲＨ－２细胞不能在经细胞融合大鼠肝癌疫苗免疫的大鼠体内致瘤，而ＮＢＴ－Ⅱ细胞可致瘤；事先清除ＣＤ４＋或ＣＤ８＋Ｔ细胞的大鼠经细胞融合大鼠肝癌疫苗免疫后仍能被肝癌ＢＥＲＨ－２细胞致瘤；而经该肝癌疫苗免疫的大鼠，清除了ＣＤ４＋细胞后不能被ＢＥＲＨ－２细胞致瘤，清除了ＣＤ８＋细胞后则可被ＢＥＲＨ－２细胞致瘤。结论：细胞融合大鼠肝癌疫苗有特异性抗肿瘤作用，这种作用与ＣＤ４＋和ＣＤ８＋Ｔ细胞有关
OBJECTIVE: To observe the anti-tumor effect of rat BERH-2 hepatoma cells and autologous activated B-cell fusion cells as vaccines, and to observe the relationship between anti-tumor effects and T cell subsets in vivo. Methods: (1) PEG-fused rat BERH-2 hepatoma cells and activated B cells were used to prepare cell fusion rat hepatocellular carcinoma vaccine; (2) Hepatoma BERH- was inoculated in rats immunized with the hepatocellular carcinoma vaccine beforehand 2 Cell and rat bladder cancer NBT-II cells were observed for the specificity of the anti-tumor effect of the liver cancer vaccine; (3) The mouse anti-rat CD4 monoclonal antibody or anti-CD8 mAb was used before or after the rat was immunized with the hepatocellular carcinoma vaccine Multiple injections to remove rat CD4+ or CD8+ T cells followed by observation of rat tumorigenicity. RESULTS: BerH-2 cells could not be tumorigenic in rats immunized with cell fusion rat hepatocellular carcinoma vaccine, and NBT-II cells could be tumorigenic; Rats that had previously cleared CD4+ or CD8+ T cells were immunized with rat hepatocellular carcinoma vaccine after cell fusion Still can be tumorigenic by liver cancer BEHR-2 cells; and rats immunized with the hepatocellular carcinoma vaccine can not be tumorigenic by BEHR-2 cells after clearing CD4+ cells, and can be tumorigenic by BERH-2 cells after clearing of CD8+ cells. Conclusion: The cell fusion rat hepatoma vaccine has specific anti-tumor effect, which is related to CD4+ and CD8+ T cells.